OpSens to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesday, July 13, 2021


Conference call to be conducted at 11:00 am ET

QUEBEC CITY, July 7, 2021 /CNW Telbec/ -Opsens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will report financial results for its third quarter of fiscal year 2021, ended May 31, 2021, on Tuesday, July 13, 2021, before the open of the market. The Company has scheduled a conference call the same day, at 11:00 am ET, to review the results.

Interested parties can access the conference call by dialing (833) 756-0865 or (412) 317-5754 or can listen via a live Internet webcast, available in the Investors section of the Company's website at https://opsens.com/investors/ or at https://www.webcaster4.com/Webcast/Page/2512/41951.  

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10158097. A webcast replay will be available in the Investors section of the Company's website at https://opsens.com/investors/ or at https://www.webcaster4.com/Webcast/Page/2512/41951.  

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly on interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesion access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.


Company Codes: OTC-QX:OPSSF, Toronto:OPS, OTC-BB:OPSSF

Back to news